Cheplapharm Arzneimittel

The core of Cheplapharm's business model is the acquisition of mature, off-patent, and niche branded pharmaceutical products from major industry players like Merck, Roche, AstraZeneca, and Sanofi. This asset-light approach focuses on acquiring intellectual property rights and then outsourcing manufacturing, distribution, and marketing activities, which eliminates in-house research and development costs. Revenue is generated through the global sales of this diversified product portfolio, which includes over 125 branded products and more than 3,200 marketing authorizations across 145 countries. This strategy has resulted in consistent double-digit annual growth and a high degree of geographical and product diversification.

Cheplapharm's portfolio is extensive, covering a wide range of therapeutic areas including cardiology, oncology, gastroenterology, and emergency medicine. Key acquired products include well-known brands such as Xenical (anti-obesity), Dilatrend (beta-blocker), Vesanoid (leukemia medication), and Rohypnol (sleep medicine). The company manages the entire lifecycle of these established drugs, ensuring their continued availability for patients worldwide and serving a global market without being overly reliant on any single country for its sales. The firm actively seeks out and integrates products that larger companies intend to divest for strategic reasons, thereby extending the commercial life of these medicines. This has proven to be a robust model, with acquisitions being a primary driver of the company's significant revenue and EBITDA growth.